The FDA has approved Biogen’s (BIIB) Alzheimer’s drug. Brad Loncar, CEO of Loncar Investments, talks about the impact of the Biogen drug approval as well as the recent activity in the health care sector. He also discusses how Biogen’s treatment compares to others in the pipeline and what he believes is the next catalyst in the health care sector. Tune in to find out more.
16 Jun 2021
Market On Close
05 Apr 2022
Trading 360
18 Apr 2022
Trading 360
11 Apr 2022
Morning Trade Live
18 Mar 2022
Morning Trade Live
23 Mar 2022
The Watch List
28 Apr 2022